Adaptimmune Therapeutics plc (473A) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.490x

Based on the latest financial reports, Adaptimmune Therapeutics plc (473A) has a cash flow conversion efficiency ratio of 0.490x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-34.78 Million ≈ $-40.66 Million USD) by net assets (€-70.96 Million ≈ $-82.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 473A net asset quality index to measure how much of total assets are equity-financed.

Adaptimmune Therapeutics plc - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Adaptimmune Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Adaptimmune Therapeutics plc (473A) cash flow quality to evaluate the quality of earnings relative to operating cash generation.

Adaptimmune Therapeutics plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Adaptimmune Therapeutics plc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Shuang-Bang Industrial TWO:6506	0.035x
Oceanpal Inc NASDAQ:OP	-0.007x
MeVis Medical Solutions AG XETRA:M3V	0.005x
OS Therapies Incorporated NYSE MKT:OSTX	-1.000x
Minesto AB ST:MINEST	-0.057x
Acuvi AB ST:ACUVI	0.000x
UBIVELOX Inc KQ:089850	-0.048x
Goodyear (Thailand) Public Company Limited BK:GYT	0.033x

Annual Cash Flow Conversion Efficiency for Adaptimmune Therapeutics plc (2016–2024)

The table below shows the annual cash flow conversion efficiency of Adaptimmune Therapeutics plc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Adaptimmune Therapeutics plc worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€11.85 Million ≈ $13.85 Million	€-73.21 Million ≈ $-85.59 Million	-6.178x	-73.28%
2023-12-31	€39.51 Million ≈ $46.19 Million	€-140.88 Million ≈ $-164.70 Million	-3.565x	-105.92%
2022-12-31	€81.88 Million ≈ $95.72 Million	€-141.77 Million ≈ $-165.74 Million	-1.731x	-3423.82%
2021-12-31	€205.96 Million ≈ $240.79 Million	€10.73 Million ≈ $12.54 Million	0.052x	+133.17%
2020-12-31	€341.23 Million ≈ $398.93 Million	€-53.59 Million ≈ $-62.65 Million	-0.157x	+82.74%
2019-12-31	€123.64 Million ≈ $144.55 Million	€-112.51 Million ≈ $-131.53 Million	-0.910x	-115.21%
2018-12-31	€246.88 Million ≈ $288.63 Million	€-104.39 Million ≈ $-122.04 Million	-0.423x	-58.01%
2017-12-31	€202.98 Million ≈ $237.31 Million	€-54.31 Million ≈ $-63.50 Million	-0.268x	+7.70%
2016-12-31	€166.14 Million ≈ $194.24 Million	€-48.17 Million ≈ $-56.31 Million	-0.290x	--

About Adaptimmune Therapeutics plc

F:473A Germany

Market Cap

$50.20 Million

€42.94 Million EUR

Market Cap Rank

#22425 Global

#1982 in Germany

Share Price

€0.16

Change (1 day)

+6.58%

52-Week Range

€0.03 - €0.25

All Time High

€12.93